137
Participants
Start Date
March 30, 2021
Primary Completion Date
March 10, 2023
Study Completion Date
December 12, 2025
DS-1062a
DS-1062a will be administered as an intravenous (IV) infusion once every 3 weeks
National Taiwan University Hospital NTUH, Taipei
Koo Foundation Sun Yat-Sen Cancer Center, Taipei
Samsung Medical Center, Seoul
NYU Langone Medical Center, New York
University of Turin San Luigi Hospital, Orbassano
Weill Cornell Medical College, New York
Taipei Veterans General Hospital, Taipei
New York Cancer and Blood Specialists, Port Jefferson
APHM - Hopital Nord, Marseille
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan
Istituto Europeo di Oncologia, Milan
The Office of Dr. Frederick P. Smith MD, Chevy Chase
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda
Hospital Regional Universitario Malaga, Málaga
Virginia Cancer Specialists, Athens
Medizinische Hochschule Hannover, Hanover
CHU Toulouse Hopital Larrey, Toulouse
Mayo Clinic, Jacksonville
Sarah Cannon Research Institute at Florida Cancer Center, North, Gainesville
AdventHealth Orlando, Orlando
Boca Raton Regional Hospital, Boca Raton
Moffitt Cancer Center, Tampa
Seattle Cancer Care Alliance, Seattle
Sarah Cannon Research Institute at Florida Cancer Center, South, Port Charlotte
Sarah Cannon Research Institute, Nashville
Sarah Cannon Research Institute at Tennessee Oncology - Chattanooga, Chattanooga
Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna
Azienda Ospedaliera Arcispedale Santa Maria, Reggio Emilia
Azienda Ospedaliero Universitaria di Parma, Parma
University Hospital of Nantes, Nantes
University Hospitals Case Medical Center, Cleveland
University of Michigan, Detroit
Universitaet zu Koeln - Uniklinik Koeln, Cologne
Mayo Clinic, Rochester
Avera Cancer Institute Sioux Falls, Sioux Falls
IKF Krankenhaus Nordwest, Frankfurt am Main
Washington University School of Medicine, St Louis
Hopitaux Universitaire de Strasbourg- Nouvel Hopital Civil, Strasbourg
CHU Louis Pradel, Lyon
Centre Leon Berard, Lyon
Thoraxklinik Heidelberg, Heidelberg
Thoraxklinik Heidelberg gGmbH, Heidelberg
National Cheng Kung University Hospital, Tainan City
Institut Curie, Paris
Mary Crowley Cancer Research, Dallas
University of Texas MD Anderson Cancer Center, Houston
Asklepios Fachklinik Muenchen-Gauting, Gauting
Centre Hospitalier Intercommunal Toulon La Seyne sur mer Hopital Sainte-Musse, Toulon
Mayo Clinic, Phoenix
UCLA, Santa Monica
University of California San Diego, La Jolla
Gustav Roussy Cancer Campus Grand Paris, Villejuif
Azienda Ospedaliera Universitaria Policlinico-OVE, Catania
Kadlec Clinic Hematology and Oncology, Kennewick
Seoul National University Bundang Hospital, Seongnam-si
Massachusetts General Hospital Cancer Center, Boston
Dana Farber Cancer Institute, Boston
XCancer / Regional Cancer Care Associate (Astera), East Brunswick
National Koranyi Institute for TB and Pulmonology, Budapest
Pulmonology Hospital Törökbálint, Törökbálint
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
Fujita Health University Hospital, Toyoake-shi
National Cancer Center Hospital East, Kashiwa-shi
Hokkaido Cancer Center, Sapporo
Kyoto University Hospital, Kyoto
Niigata Cancer Center Hospital, Niigata
Kansai Medical University Hospital, Hirakata-shi
Osaka City General Hospital, Osaka
Osaka International Cancer Institute, Osaka
Kindai University Hospital, Ōsaka-sayama
Shizuoka Cancer Center, Nagaizumi-chō
Tokushima University Hospital, Tokushima
National Cancer Center Hospital, Chuo Ku
The Cancer Institute Hospital of JFCR, Koto-Ku
Aichi Cancer Center Hospital, Aichi
The Netherlands Cancer Institute, Amsterdam
Erasmus MC, Rotterdam
Seoul National University Hospital, Seoul
Severance Hospital, Seoul
Asan Medical Center, Seoul
Hospital General Universitario de Alicante, Alicante
Hospital Universitario Vall dHebron, Barcelona
Hospital Clinic i Provincial de Barcelona, Barcelona
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Daiichi Sankyo
INDUSTRY